Product
Liquid Alpha1-Proteinase Inhibitor
Aliases
Liquid Alpha1-Proteinase Inhibitor (Human)
2 clinical trials
2 indications
Indication
Alpha-1 Antitrypsin DeficiencyIndication
COVID-19Clinical trial
A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin DeficiencyStatus: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19Status: Terminated, Estimated PCD: 2021-12-13